Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

Rhea-AI Summary

Biogen (Nasdaq: BIIB) is set to present the EMBARK trial design for its investigational Alzheimer’s therapy, aducanumab, at the 2021 AAN Annual Meeting on April 17, 2021. This Phase 3b, open-label study aims to evaluate the long-term safety and efficacy of aducanumab in Alzheimer’s patients. The presentation will be led by Dr. Carmen Castrillo-Viguera. More details can be accessed on Biogen's investor website, where an archived version will also be available post-event.

Aducanumab, a human monoclonal antibody, has shown promise in slowing cognitive decline in Alzheimer’s disease.

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting.

AAN Poster Presentation Details:

• Saturday, April 17, 2021, 8:00 a.m. ET – EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer’s disease with Carmen Castrillo-Viguera, M.D., Senior Medical Director, Clinical Development at Biogen
  

To access the poster presentation, please go to the Investors section of Biogen’s website at investors.biogen.com. Following the event, an archived version will be available on the website.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

About Aducanumab
Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer’s disease. Based on clinical data from patients with Mild Cognitive Impairment due to Alzheimer’s disease and mild Alzheimer’s disease, aducanumab has the potential to impact underlying disease pathophysiology, slow cognitive and functional decline and provide benefits on patients’ ability to perform activities of daily living, including conducting personal finances, performing household chores, such as cleaning, shopping and doing laundry, and independently traveling out of the home. If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for individuals living with Alzheimer’s.

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Since October 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally.

MEDIA CONTACT: David Caouette          +1 617 679 4945 public.affairs@biogen.com

INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com

FAQ

What is the EMBARK trial related to Biogen's Alzheimer’s therapy aducanumab?

The EMBARK trial is a Phase 3b, open-label study focused on evaluating the long-term safety and efficacy of aducanumab in Alzheimer’s disease patients.

When will Biogen present the EMBARK trial at the AAN Annual Meeting?

Biogen will present the EMBARK trial on April 17, 2021, at the virtual American Academy of Neurology Annual Meeting.

Who will lead the EMBARK trial presentation for Biogen?

Dr. Carmen Castrillo-Viguera, Senior Medical Director at Biogen, will lead the EMBARK trial presentation.

Where can I find more information about Biogen’s EMBARK trial presentation?

More information and access to the presentation can be found on Biogen's investor website post-event.

What is aducanumab and its significance in Alzheimer’s treatment?

Aducanumab is an investigational human monoclonal antibody that may slow cognitive decline in Alzheimer’s patients and could significantly change disease management.